Preclinical development of T cells engineered to express a T cell antigen coupler (TAC) targeting Claudin 18.2-positive solid tumors.
Xu SX, Wang L, Ip P, Randhawa RR, Benatar T, Prosser SL, Lal P, Khan AN, Nitya-Nootan T, Thakor G, MacGregor H, Hayes D, Vucicevic A, Mathew P, Sengupta S, Helsen CW, Bader AG.
Xu SX, et al.
Cancer Immunol Res. 2024 Oct 15. doi: 10.1158/2326-6066.CIR-24-0138. Online ahead of print.
Cancer Immunol Res. 2024.
PMID: 39404622